Cnpair Biotech Co., Ltd.
Cnpair Biotech Co., Ltd. is a professional provider which concentrates on IVD core materials, including antibodies and proteins, and we are dedicated to developing and delivering highly competitive antibodies and proteins with outstanding performance for IVD assay developments, productions and research applications. With expended knowledge on core materials research and in-vitro diagnostic assays development, we started to provide technology support and hi-quality core materials to IVD industry, and in 2017 Cnapir Biotech Co., Ltd. was founded in Hangzhou.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Our products cover many aspects, including infectious diseases, tumor biomarkers, cardiac markers, inflammation biomarkers and hormone markers. Those products are applied extensively in China and abroad, and we are cooperating with manufacturers of all sizes in IVD industry, even including some top players in the industry.
Currently, Cnpair has R&D and manufacture facilities in Hangzhou, and sale offices in Shanghai, Hangzhou and San Francisco Bay Area. Besides tangible products, professional consulting service on in vitro diagnostics development and production is also offered to our valuable customers. With consistent efforts, we have been striving for superior customer satisfaction driven by the profession, teamwork and commitment of each Cnpair associate, and our vision is “Good Quality for Health”.
Mission
To Be World-Leading IVD Core Materials Provider
Value
Profession, Teamwork, Commitment
Vision
Good Quality for Health
R&D Advantages
Introduction to the technology platform
Our company has gathered the earliest professionals engaged in the development and application of diagnostic raw materials in China, and has nearly 20 years of experience in the development of in vitro diagnostic materials. The E. coli expression system technology platform developed by us is the first technology platform for the in vitro diagnosis and production of recombinant antigens in China. It is also the first high-efficiency safe and secure technology platform for the development of genetic engineering vaccines. Based on the characteristics of E. coli expression systems, a complete set of techniques for purification, in vitro assembly and quality control of virus-like particles was established. At present, our company has used this technology platform to develop a large number of antigens and recombinant proteins for in vitro diagnostic reagents, such as HIV, HCV, TP, HEV, etc., and will continue to use this technology platform to develop more diagnostic antigens in the future.
Antibody production technology
The antibody production technology has been in existence for a long time and is one of the most widely used technologies in the field of biotechnology. Diagnostic antibodies and antibody drugs developed based on this technology have occupied an important position in the field of biomedicine. Based on the unique myeloma cell fusion screening technology, our company has formed a set of specific high-affinity antibody production technology processes after decades of development. Based on this technical process, we have developed many star products, such as HIV P24 monoclonal antibody, TB-IGRA (IFN-Y) monoclonal antibody, PCT, CRP, PIIINP, HBsAg, cTnT, MYO, etc., creating a huge economy and social benefits.